CHA sent a comment letter to the FDA on draft guidance that recommends how and when manufacturers provide additional information in drug shortage notifications to the agency. Our letter urges the FDA to address the specific challenges facing the pediatric drug supply chain through transparency requirements, developing proactive shortage mitigation plans, and ensuring an accounting of pediatric drugs on the FDA drug shortages list.
CHA Submits Comments on FDA Drug Shortage Guidance
Children’s Hospital Association sends a comment letter to the FDA on draft drug shortage guidance to highlight the need for an efficient pediatric supply chain.
Related Content
High-Cost Therapies for Pediatrics
Addressing a Public Health Crisis
Pediatric Workforce Shortages Persist in 2024
High-Cost Therapies for Pediatrics
Pediatric HCTs are innovative and lifesaving or life-altering treatments for children with chronic, rare, and complex conditions.
Sep. 06, 2024
Addressing a Public Health Crisis
Children's hospitals must work together to make communities safe for kids to grow and thrive.
Sep. 05, 2024
Pediatric Workforce Shortages Persist in 2024
Children’s hospitals continue to experience shortages across pediatric care fields with an outsized impact on mental and behavioral health specialties.
July 19, 2024
